Claima6403777ad00251b19505c95c1e7cfbbae7f0819d6c88fe05fe5d2fee9e5ce8a·My Arguments

Claim

Across meta-analyses of GLP-1 receptor agonist trials, major adverse cardiovascular events are reduced by roughly 12–20% with concordant reductions in cardiovascular and all-cause mortality, and the cardiovascular benefit holds independently of diabetes status.

Evidence (1)

Cardiovascular outcomes of semaglutide and tirzepatide (2025)

Pooled GLP-1 RA evidence shows ~12-20% MACE reduction with mortality benefit, independent of diabetes status.

https://www.nature.com/articles/s41591-025-04102-x_reference.pdf

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/a6403777ad00251b19505c95c1e7cfbbae7f0819d6c88fe05fe5d2fee9e5ce8a"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

View full deliberation Join & respond